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Abstract Understanding the complex events leading to for-
mation of an epithelial-based organ such as the breast requires
a detailed insight into the crosstalk between epithelial and
stromal compartments. These interactions occur both through
heterotypic cellular interactions and between cells and matrix
components. While in vivomodels may partially capture these
complex interactions, there is a need for in- vitro models to
study these events. In this review we discuss cell-cell interac-
tions in breast development focusing on the stem cell niche
and branching morphogenesis. Given the recent understand-
ing that the basic developmental events underlying branching
morphogenesis are closely related to pathways important to
cancer progression, i.e. epithelial plasticity and epithelial to
mesenchymal transition (EMT), we will also discuss aspects
relevant to cancer progression. In cancer, the adoption of mes-
enchymal phenotype by the malignant cells allows stromal
invasion and subsequent intravasation to blood- or lymphatic
vessels, a route that is a prerequisite for metastasis. A number
of publications have demonstrated that tumor initiating cells,
sometimes referred to as cancer stem cells adapt an EMT
phenotype that renders them more resistant to apoptosis and
drug therapy. The mechanism behind this phenomenon is cur-
rently unknown but this may partially explain relapse in breast
cancer patients. Increased understanding of branching mor-
phogenesis in the breast gland and the regulation of EMT
and its reverse process mesenchymal to epithelial transition
(MET) may hold the keys for future development of methods/
drugs that neutralize the invading properties of cancer cells.
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Abbreviations
BRENCs Breast endothelial cells
EMT Epithelial to mesenchymal transition
ERα Estrogen receptor α
FGF Fibroblast growth factor
HUVEC Umbilical vein endothelial cells
MET Mesenchymal to epithelial transtion
miRNAs MicroRNAs
MMPs Matrix-metalloproteases
rBM Reconstituted basement membrane
TDLU Terminal duct lobular unit
TEB Terminal end bud
VEGF Vascular endothelial growth factor
Introduction
Epithelial cells serve multiple functions in the human body.
These include barrier functions (skin, trachea), hormonal secre-
tion (pituitary gland, adrenal glands and Langerhans islands in
the pancreas), exocrine secretion (prostate, pancreas, salivary
gland, breast gland), absorption, filtration and gas exchange
(intestine, kidneys and lungs). To serve its function, epithelial
cells have adhesion properties that generate tight layer(s) of
squamous, cuboidal or columnar epithelium dependent on
location and function within the human body. Due to the
immediate exposure of epithelial tissue to external environment
cellular remodeling and renewal occurs relatively fast, meaning
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that new cells are continuously replacing older cells. Epithelial
organs therefore contain stem cells that are responsible for the
continuous cellular remodeling [1]. Furthermore, it has been
suggested that epithelial cancers originate in these stem cells
or cells that have acquired stem cell properties [1–3]. The
female breast gland is a unique organ in that most of its devel-
opment occurs postnatally. The breast gland undergoes repeated
cycles of cell proliferation, differentiation and involution from
menarche to menopause at which point hormonal signals, or
lack thereof, cause cell death by triggering a combination of
apoptosis and senescence [4–6]. These cellular remodeling
processes are most prominent during pregnancy and lactation
when the breast gland becomes fully differentiated.
The branching nature of the epithelial ducts in the breast
requires a level of phenotypic plasticity enabling cells to invade
the underlying stroma. Cells need to transit from robust epithe-
lial cell-cell binding to a more mobile state to facilitate migra-
tion. The cells can achieve this using distinct mechanisms
including collective migration [7, 8] or epithelial to mesenchy-
mal transition (EMT) where leading cells at the tip of the
branching structures acquire mesenchymal characteristics that
facilitate migration into the surrounding stroma [9]. EMT is a
fundamental process in normal embryonic development, partic-
ularly during formation ofmesoderm, neural crest formation and
heart valve development [10]. EMT is also an important process
during wound healing. Finally, EMT has been closely linked
with breast cancer progression where tumors of certain
sub-groups have been demonstrated to be driven by cancer stem
cells that have acquired mesenchymal traits that greatly en-
hances their tumorigenicity and metastatic potential [9, 11, 12].
In this review we will focus on the cellular and molecular mech-
anisms of breast morphogenesis and EMT and its reversed pro-
cess mesenchymal to epithelial transition (MET) and how these
processes can be recapitulated in stromal-rich three-dimensional
cell culture assays. In addition, we will discuss the clinical rele-
vance of EMT, MET and cancer stem cells in breast cancer in
terms of diagnostic value, prognosis and therapeutic application.
Normal Mammary Gland Development
The breast gland, somewhat uniquely, develops in different
stages separated in time often by years or decades. In early
embryonic mammary gland development, the formation of
the mammary epithelial placodes in the skin is a critical event.
These epithelial buds invade the underlying mesenchyme to
form a rudimentary ductal systems embedded in stroma that
develops along with the mammary epithelium [13]. Most stud-
ies focusing on mammary development are based on mouse
models due to ease of access and great availability of differently
mutated mouse strains. Although critical developmental events
may be conserved through evolution there are notable differ-
ences between humans and mice. Importantly, there are
differences regarding the stroma surrounding the branching
epithelium. In humans, the epithelium is embedded in cell-
rich collagenous stroma while in mice the stromal component
is mostly adipose tissue commonly referred to as the mammary
fat pad [13, 14] (Fig. 1). In addition, while the structure of the
glandular tissue is fundamentally similar in mice and humans,
the human branching tree displays a markedly higher complex-
ity that is partly explained by its greater size. The terminal
mammary epithelial structures are different in mice and
humans. In mice the epithelial ducts terminate in the end bud
(TEB). In contrast the human female breast is more elaborate;
terminating in ductal lobular units (TDLUs) that are character-
ized by clusters of acini and small ductules [14].
Fig. 1 Histological differences between the human breast and mouse
mammary gland. The functional unit of the human breast gland is the
terminal duct lobular unit (TDLU). This structure is composed ofmultiple
acini and small ductules and is embedded in a collagenous stroma. The
stroma can be divided in two, the interstitial stroma, between TDLUs and
ducts, and the looser cellular-rich lobular stroma, within TDLUs. The
Human mammary tissue along with the stroma, is in turn embedded in
fat tissue. In mice, the mammary gland is composed of a series of
branching ducts, terminating in the terminal end bud (TEB). Compared
to human breast tissue, the collagenous stroma surrounding the mouse
mammary epithelium has a much smaller volume (periductal stroma), so
the epithelial structure is enclosed by fat tissue. Adapted from Parmar
et al. [13] with permission
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In humans, breast glands are similar in both sexes until the
onset of puberty. In women, the second phase of development
occurs during puberty. This phase is characterized by marked
stromal and epithelial proliferation via hormonal stimulation.
Estrogen signaling through the estrogen receptor α (ERα) is
the primary force driving ductal branching and elongation, while
progesterone signaling through its cognate receptor is required
for proliferation and terminal differentiation in the TDLU [15].
The epithelial tubes elongate extensively at this stage and under-
gomore pronounced branching than during the embryonic stage.
The final major developmental phase involves pregnancy
and lactation. During pregnancy, further branching occurs and
the cells within the TDLUs proliferate extensively to prepare
for the final functional stage of lactation. The luminal epithelial
cells finally reach their terminally differentiated state during the
lactation period. At all other time periods, the luminal epithelial
cells are considered to be in an immature, non-functional state.
After lactation, the gland undergoes involution, characterized
by massive epithelial apoptosis and return to a near pre-
pregnancy non-functioning state. It is well established that the
duration of the interval between the pubertal stage and first
pregnancy is major risk factor for breast cancer. In that regard
it has been proposed that repeated hormone stimulation of the
stem cell niche in the course of repeated menstrual cycles prior
to first pregnancy may be an important early event in breast
carcinogenesis [16]. Overall, pregnancy leads to a long-term
protective effect against breast cancer, presumably via a deple-
tion of the stem cell reservoir [17].
The putative mammary epithelial stem cell is responsible for
growth, maintenance and late developmental generation and re-
generation (at repeated pregnancies) seen through these distinct
different phases of early and late development. The mouse
mammary stem cell has been fairly well characterized using
genetic techniques for tracking and transplantation assays in
cleared mammary fat pad model [18, 19]. This cell type, char-
acterized by a Lin−CD29hiCD24+ immunophenotype, can at a
single cell level regenerate the mouse mammary epithelium.
The immature mammary gland stem cells have been located
in the so-called peripheral cap cells of the mouse terminal end
buds. Furthermore, in addition to the mammary stem cell, there
is evidence for a hierarchical structure within the mammary
epithelial tree, with both lobule- and duct-restricted progenitor
cells [20]. While progenitor cells exist within the luminal pop-
ulation, these cells and their descendants have a relatively short
lifetime in the gland, and are replaced in the course of a few
months. The long term repopulating cells within ducts reside in
the myoepithelial/basal layer. These cells give rise to transit
amplifying cells within both luminal and myoepithelial layers
as evidenced using lineage tracing, clonal expansion of cells
that express a single reporter fluorochrome [21].
In comparison to the mouse, the human mammary epithelial
stem cell is less well defined. There are, however, several stud-
ies that have isolated and/or characterized human breast epithe-
lial cells with stem cell properties that have to a varying degree
been able to recapitulate the human breast epithelial phenotype
[22–25]. Using cells from reductionmammoplasties cultured in
three dimensional (3D) reconstituted basement membrane
(rBM) matrix we and others have been able to isolate and
characterize putative human mammary stem cells that are able
to regenerate a branching bilayered epithelium (Fig. 2) with
lineage committed luminal and myoepithelial cells [23, 26].
These cells have a subrabasal location in the breast gland, re-
siding between the myoepithelial and luminal cells. They were
initially isolated on the basis of epithelial specific antigen
(ESA/EpCAM)) positive and sialomucin (MUC-1) negative
immunophenotype. Understanding how the breast epithelium
Fig. 2 Breast morphogenesis in 3D cell culture. During conventional cell
culture, cells proliferate in a monolayer forming a sheet of cells at the
bottom of the culture dish. This is an environment that is highly abstract to
cells that in vivo find them self in a 3D environment. This may have great
effects on gene expression resulting in altered phenotype. When
seeded in a 3D matrix such as reconstituted basement membrane (rBM)
matrix the same cells can undergo drastically different morphogenesis,
forming polarized spheres with a central lumen, or as for certain cell lines,
branching morphogenesis
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including breast epithelial stem cells interacts with the sur-
rounding stroma is crucial as these studies may shed light on
breast morphogenesis, cellular remodeling and heterotypic in-
teractions during breast cancer progression.
Epithelial-Stromal Interactions
The growth and branching morphogenesis of breast epitheli-
um is under instructive influences of the surrounding stroma.
The breast stroma is composed of collagenous extracellular
matrix (ECM) and resident stromal cells including fibroblasts,
immune cells, adipocytes and endothelial cells [14, 27]. In
contrast, the mouse mammary gland is enclosed by fat tissue
with fewer stromal cells in direct contact with epithelial tissue
[13, 14] (Fig. 1). Fibroblasts and immune cells are acknowl-
edged as important players in breast morphogenesis and neo-
plasia [28–30] while endothelial cells have been largely
neglected except in angiogenesis during cancer growth.
Fibroblasts are the main producers of ECM and they are also
known to secrete growth factors and remodeling proteins such
as matrix-metalloproteases (MMPs) that stimulate prolifera-
tion and branching morphogenesis of breast epithelium [31].
It has also been shown that priming of mouse tissue with
human fibroblasts before implantation of human epithelial
xenografts improves the mouse model for studying molecular
signals during human breast branching morphogenesis [32].
Endothelial cells have previously been pictured as passive
constituents of the conductive system transporting oxygen and
nutrients towards tissues and waste products away. In addi-
tion, they have more recently been identified as critical regu-
lators of the stem cell niche and organogenesis in many tis-
sues, such as brain, liver and pancreas [33–35]. In the prostate,
post-castration stimulation with androgens expands the vascu-
lature before epithelial recovery suggesting that endothelial-
derived signals may be vital for epithelial growth [36]. We
have recently shown that endothelial cells facilitate growth
and branching morphogenesis of prostate epithelial cells when
cocultured in reconstituted basement membrane (rBM) [37].
Evidence supporting the role of the endothelium in modulat-
ing the branching epithelial morphogenesis in the lung has
also emerged. Like in the prostate, we have shown that endo-
thelial cells profoundly stimulate growth and branching mor-
phogenesis of lung epithelium in 3D culture. In this assay a
basal-like human pulmonary epithelial cell line (VA10) with
stem cell properties [38] undergoes branching morphogenesis
when cocultured with endothelial cells. These branching col-
onies were reminiscent of tubulo-alveolar-like structures [39].
Recently, a critical endothelial- epithelial signaling interaction
was reported in a study using a mouse lung model. Recovery
of lung tissue following pneumonectomy was shown to be
mediated by an endothelial-to-epithelial signaling cascade in-
volving the matrix as an intermediary player. The pulmonary
endothelial cells were shown to express and secrete matrix
metalloproteinase 14 (MMP14) in response to vascular endo-
thelial growth factor (VEGF) and fibroblast growth factor
(FGF) stimulation. The endothelial derived MMP14 contrib-
uted by generating EGF-like ligands by cleaving native lam-
inin 5-γ2 in the matrix thus activating EGF receptors (EGFR)
expressed on the surface of alveolar epithelial cells [40].
Analogous to the lung, we have shown that microvessels in a
normal human breast are abundant and in close proximity to the
epithelial cells of the TDLUs [41]. Studies have confirmed that
during the menstrual cycle and pregnancy, vascularity of the
normal mammary fluctuates in correlation with hormonal levels
[42]. Interaction between human umbilical vein endothelial cells
(HUVEC) and premalignant breast epithelial cells has been
shown to support proliferation of endothelial cells and induce
ductal-alveolar branchingmorphogenesis and hyperplasia of pre-
malignant breast epithelial cells [43, 44]. We have improved the
isolation protocol and conditions for long term culture of breast
endothelial cells (BRENCs) [41]. Using BRENCs we have de-
veloped a novel three dimensional co-culture model, where pri-
mary breast endothelial cells are seeded with epithelial cells in
3D rBM. Using this assay we have shown that BRENCs stimu-
late proliferation of both primary luminal- and myoepithelial
cells. Furthermore, the endothelial cells stimulated the growth
and cloning efficiency of normal and malignant breast epithelial
cell lines and this was contributed by soluble factors [45].
When BRENCs are co-cultured in 3D rBM with D492, a
breast epithelial cell line with stem cell properties, we observe
increased branching morphogenesis, supporting the data that
BRENCs contribute to regulation of branching epithelial mor-
phogenesis. D492 was initially established from EpCAM pos-
itive, MUC1 negative suprabasal cells. D492 generate luminal
and myoepithelial cells in culture and in 3D rBM it forms
elaborate branching structures reminiscent of TDLU in situ
[23]. Interestingly, in this co-culture model we also observe
spindle-like colonies indicating that BRENCs can induce
EMT in D492 cells [46]. Isolation of these spindle like cells
fromD492 resulted inmesenchymal-like subline referred to as
D492M (Fig. 3). D492M, shows a complete mesenchymal
phenotype lacking epithelial markers such E-cadherin and
cytokeratins but expressing mesenchymal markers such N-
cadherin, vimentin, fibronectin, and FOXC2 [46].
Cellular and Molecular Alteration During EMT
EMT has in recent years caught the attention of the clinical
research community as an intrinsic mechanism in pathogenic
processes such as fibrosis and progression of many types of
cancer including breast cancer [47–49]. EMT is a term used to
describe morphological change of epithelial cells from regu-
larly arranged cuboidal, columnar or squamous form to a fi-
broblast or stellate appearance accompanied by increased
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occurrence of cell protrusions. This transition involves reor-
ganization of the rigidly layered epithelium to a more loosely
connected assembly of cells with increased migratory poten-
tial. Concurrently, each cell undergoing EMT rearranges its
cytoskeleton allowing transformation to the mesenchymal
trait resulting in a spindle-like phenotype. In developmental
biology, EMT is a well-known theme, especially during gas-
trulation. Prior to gastrulation, the cell layer at the site of
ingression has a typical epithelial arrangement characterized
by apico-basal polarity, adherens junction and connection to
basement membrane. The ingression is initiated by localized
disruption of cell-to-cell adhesion altering cell morphology
and causing breakdown of the basal membrane and finally,
mass migration of the resulting mesenchymal cells into new
territories. The sequence can be reversed as the migrating cells
form settlements and new epithelial like layers form in a pro-
cess often referred to as mesenchymal-to-epithelial transition
(MET). Thus, EMT and MET represent recurrent programs
enhancing cell and tissue plasticity necessary for the complex
tissue remodeling during embryonic development [10].
One of the critical epithelial characteristics lost during
EMT is cell-to-cell adhesion. This property is mediated by
adherens junctions that are based on transmembrane proteins
including cadherins, connecting adjacent cells via homophilic
attachments made by their extracellular domains. Importantly,
monitoring a switch from the expression of epithelial cadherin
(E-cadherin) to a type of cadherin expressed by neurons and
fibroblasts (N-cadherin), is the most commonly used method
to assess EMTon a molecular level [50]. Alteration of cell-to-
cell contact is also enforced through changes in desmosome
expression allowing increased cell mobility. An important
feature of EMT is the down-regulation of tight junction
proteins including occludin and claudins constituting the
trans-epithelial barrier [51]. In the normal tissue, occludin
and claudins facilitate strong epithelial binding, and during
EMT these proteins are progressively lost. In the breast
epithelium, EMT is accompanied by a number of additional
cytoskeletal changes including down-regulation of epithelial
cytokeratins (CK5/6, CK8, CK14, CK17, CK18 and
CK19), upregulation of vimentin, and smooth muscle actin,
resulting in cells closely resembling myofibroblasts, a pop-
ulation of fibroblasts important for stromal tissue remodel-
ing that are commonly activated during wound healing
[52]. Finally, the EMT process is accompanied by loss of
apical-basal polarity and anchoring junctions attaching the
cells to the extracellular matrix and/or basement membrane.
Cells that have undergone full EMT are practically indistin-
guishable from stromal fibroblasts [51].
Extracellular signals triggering EMT may channel through
multiple pathways including the transforming growth factor
Fig. 3 Generation of the D492M
cell line. The epithelial cell line
D492 was established from
normal breast tissue [23]. When
cultured in 3D, it forms branching
colonies reminiscent of the
TDLU. In co-culture with breast
endothelial cells, this cell line can
form mesenchymal colonies.
When branching colonies are
isolated from 3D culture and re-
plated, they form both branching
andmesenchymal colonies during
secondary co-culture, while the
mesenchymal colonies only give
rise to additional mesenchymal
colonies. Amesenchymal cell line
(D492M) was established from a
mesenchymal colony using single
cell cloning. Adapted from
Sigurdsson et al. [46] with
permission
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beta (TGFβ), Notch, WNT, hedgehog, receptor tyrosine ki-
nases (RTKs) and nuclear factor kappa-light chain enhancer of
activated B-Cells (NFkB) [12, 53]. The most potent extracel-
lular EMT inducer in breast epithelium and breast cancer is
TGFß which promotes heterodimerization of TGFß receptors
(Type I and II) following binding to the cell surface. TGFß
ligand binding further triggers trans-phosphorylation of the
cytosolic receptor domain which then enables them to phos-
phorylate downstream targets, the SMAD proteins.
Phosphorylated SMADs dimerize in the cytosol, allowing en-
try to the nucleus and binding to promoter regions of target
genes.
In view of the importance of EMT in promoting pathogen-
esis, identifying cells that may serve as paracrine source of
TGFß or other EMT inducing ligands in cancerous or fibrotic
tissue is being increasingly emphasized. Likely candidates
include leukocytes, platelets, endothelial cells and cancer as-
sociated fibroblasts (CAFs) [54–57]. Immunohistochemical
staining in breast cancer suggests that the microvessels in
the vicinity of invading cancer cells may be a critical factor
for adapting an EMT phenotype although the paracrine mech-
anisms contributing to this effect have not been fully elucidat-
ed [46].
The ability of TGFß to confer EMT seems to be context
specific and in some models epithelial cells are susceptible to
other factors. For instance, contact dependent activation of the
Notch pathway through the ligand Jagged 2 has been shown to
induce EMT in colorectal cancer cells that do not adapt the
phenotype in response to TGFß treatment [58, 59]. The im-
portance of Notch signaling in breast cancer is supported by
studies showing up-regulation of Notch genes in metastases of
the brain and clinical studies showing increased mortality in
patients with high level co-expression of Notch and JAG1 in
the tumors [59–61].
The canonical Wnt signaling pathway is directly related to
the regulation of E-cadherin adhesion properties through con-
trol of its stabilizing partner ß-catenin. ß-catenin also functions
as a transcription factor that can quickly transfer from cytosol
to the nucleus in response to WNT signals where it activates
promoters of target genes by displacing the co-repressor
Groucho [62]. Wnt signaling molecules bind to the Frizzled
family of receptors that associates with various co-receptors
depending on ligand and cell type. The signal is further
channeled to the cytosol through the canonical pathway af-
fecting proteolytic control of ß-catenin or the non-canonical
pathway that is independent of ß-catenin. These different path-
ways ultimately control transcriptional regulatory factors such
as beta-catenin, SNAIL, SLUG, TWIST, ZEB1 and ZEB2
leading to increased expression of mesenchymal and de-
creased expression of epithelial markers [51].
MicroRNAs (miRNAs) have been implicated at several
levels to be involved in the regulation of EMT [63].
Although a number of miRNAs have been shown to
participate in EMT the miRNA-200 family is probably the
best known [64]. The miR-200 family is an important regula-
tor of epithelial integrity and loss of its expression is strongly
associated with EMT. MiR-200 is a repressor of ZEB1 and
ZEB2 that are the main EMT transcription factors that down
regulate E-cadherin [65]. Recently, we demonstrated that
miR-200c-141 induced MET when overexpressed in
D492M. Furthermore, we also demonstrated that ectopic ex-
pression of miR-200c-141 in D492 and D492M prevented
endothelial induced EMT. Thus, the miR-200 family and
miR-200c-141 in particular are important caretakers of epithe-
lial integrity in the human breast gland [66].
In a recent study we demonstrated that Sprouty-2 a con-
served negative feedback regulator of receptor tyrosine ki-
nases affected branching morphogenesis and EMT of D492
cells in 3D culture. In this study we showed that knocking
down Sprouty-2 in D492 resulted in large hyperplasia-like
branching structure and in coculture with endothelial cells
almost all colonies displayed mesenchymal phenotype [67].
These data implicate Sprouty-2 as an important regulator in
linking branching morphogenesis and EMT together and un-
derlines the importance of 3D cultures in experiments when
dealing with spatial and temporal biological events.
Therapeutic Intervention of EMTand Cancer Stem
Cell Phenotype
In epithelial cancer, the EMT phenotype is associated with
increased aggressiveness and metastatic behavior [12]
(Fig. 4). In breast cancer, studies have shown that EMT con-
version occur preferentially in triple negative breast cancer
including the basal-like subtype of breast carcinoma [48, 67,
68]. This subtype is characterized by a marker profile resem-
bling a breast epithelial stem cell signature [69]. Al Hadjj et al.
isolated a subpopulation of cells from breast cancer samples
(CD44high/CD24low) and demonstrated by clonal inoculation
into NOD/SCID mice that these cells contained cancer stem
cells (CSCs) as observed by clonal growth and ability to re-
generate the phenotype of the original tumor [70]. Mani et al.
showed that in immortalized human breast epithelial cells
(HMLE cell line), induction of EMT was associated with ac-
quisition of stem cell properties as measured by increased ratio
of CD44high/CD24low expression [49]. Also, these cells have
the ability to formmammosphere colonies in culture, a typical
feature of breast epithelial stem cells [49]. It is, however, de-
bated if the EMT phenotype is necessary for the occurrence of
the cancer stem cell phenotype. Leth-Larsen et al. demonstrat-
ed that CD44high/CD24low cell population with Bepitheloid^
phenotype rather than the CD44high/CD24negative with mesen-
chymal phenotype is more efficient in generating tumors in
nude mice [71]. It is, however not known if this particular cell
population is prone to EMT. The same authors have also
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demonstrated the presence of tumor initiating cells within lu-
minal epithelial tumors [72]. The relationship between epithe-
lial and mesenchymal phenotype with regard to the cell-of-
origin in breast cancer and metastatic potential is still unclear.
Typically, tissue stem cells proliferate slowly and are there-
fore more resistant to chemotherapy as many cancer drugs
specifically target proliferating cells by inducing DNA dam-
age, causing growth arrest and apoptosis. Survival statistics
underlining increased mortality in breast cancer patients with
mesenchymal elements in the primary tumor, e.g. triple nega-
tive and claudin-low breast cancers, suggests that EMT cells
are less sensitive to chemotherapeutic agents. This is further
supported by the finding that cell populations displaying an
EMT and CSC phenotype are likely to be present within re-
sidual breast cancer after conventional chemotherapy [73].
At present there is not a full understanding of the inherent
drug resistance of the EMT phenotype but several mecha-
nisms could be at play. Firstly, the mesenchymal phenotype
may be associated with higher expression of drug transporters
such as ABCB1 (also known as multidrug resistance protein
1, MDR1) and ABCG2 that actively export cytotoxic drugs.
Up-regulation of these protein pumps has been suggested as
an important protection mechanism of the cancer stem cells
that contribute to treatment failures and relapse. Although the
EMT phenotype may be a step closer to stem cell character
than the epithelial state, evidence supporting this mechanism
is lacking and treatment of patients with ABCB1 inhibitors
such as tariquidar and zosuquidar have not improved thera-
peutic response [74]. Another mechanism of how EMT may
contribute to drug resistance includes altered cell cycle dy-
namics. Cells undergoing EMT may proliferate at lower rates
or increase the proportion of quiescent cells, thereby minimiz-
ing the damaging effect of drugs targeting DNA. Moreover,
EMT may favor migration of the cancer cells to a microenvi-
ronment that is not easily targeted by drugs. The blood–brain
barrier is a simple example of such a restriction as it inhibits
diffusion of macromolecules including the antibody based
drug Herceptin. HER2 overexpressing cancer cells
transpassing the blood–brain barrier prior to drug administra-
tion, possibly as consequence of EMT reprogramming, are
thereby left untouched by the drug and may proceed to form
metastatic colonies [75].
In addition to all the above mentioned mechanisms the
number of gene expression changes in cells undergoing
EMT may also directly involve genes affecting the sensitivity
to apoptosis signals. In fact, accumulating data implicates key
EMT transcription factors directly in acquisition of chemo-
and radio-resistant cancer phenotype. As an example, a study
of ovarian cancer cells suggest that key EMT regulatory fac-
tors Slug and Snail directly promote both chemo- and radio-
resistance by suppressing p53-mediated apoptosis [76]. Snail
has also been identified as a critical regulator of EMT in
cisplatin-resistant lung cancer cells [77]. In breast cancer, an-
other master EMT regulator, ZEB1, confers resistance to radi-
ation therapy by allowing homologous recombination-
dependent DNA repair through stabilization of CHK1.
Interestingly, ZEB1 was found to be phosphorylated by
ATM which is a key signaling protein in the DNA damage
response pathway [78]. ZEB1 has additionally been identified
as a mediator of chemo-resistance in models of lung and brain
cancer and may therefore be considered a promising therapeu-
tic target [79, 80]. Interestingly, ZEB1 has higher expression
Fig. 4 Cancer progression and metastasis. Breast cancer arises as
localized lesions, most often within ducts and termed ductal carcinoma
in situ (DCIS). These tumors are encapsulated by the myoepithelial cells
(green) and a basement membrane (black line). When tumors progress to
invasive disease the myoepithelial cells are progressively lost and the
tumor breaks into the surrounding stroma, coming in contact with stromal
cellular components, such as fibroblasts andmicrovessels. Changes to the
microenvironment can induce cancer cells to undergo an epithelial to
mesenchymal transition (EMT) a process where cells acquire increased
survival and mobility. Increased mobility can lead to cells entering lym-
phoid or blood vessels and forming metastases in lymph nodes or distant
organs. After forming metastases, established tumors often re-acquire
epithelial characteristics through mesenchymal to epithelial transition
(MET). BLungs Diagram Simple^ and BBrain Human Lateral View^ by
Patrick J. Lynch, licensed under Creative Commons Attribution 2.5
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in basal-like breast cancer than luminal breast cancer. Basal-
like breast cancers seem to have a higher proportion of CSC
and they also have increased tendency to undergo EMT [81].
Since the TGFβ signaling pathway has been extensively
linked to carcinogenesis and cancer progression, the pharma-
ceutical industry has been interested in developing drugs an-
tagonizing its effect [82]. The relatively recent discoveries
placing TGFβ at the centre of EMT and formation of meta-
static disease further stimulates interest in targeting TGFβ
pathways. Some of the recently discovered inhibitors are po-
tentially useful in treating breast cancer e.g. an inhibitor of
TGFβ type I and II receptors termed LY2109761 has been
shown to reduce the metastatic formation of basal cell-like
MDA-MB-231 breast cancer cells [83]. Another example is
the recently discovered inhibitor EW-7195 that selectively
targets the TGFβ type I receptor ALK5. This inhibitor dra-
matically reduces levels of phoshorylated Smad-2, expression
of EMT phenotype and formation of lung metastases in xeno-
graft mouse models following TGFβ stimulation [84].
Since EMT in normal and cancerous tissue is likely to be
dynamically regulated by the epigenetic machinery, therapeu-
tically targeting mechanism involved in regulating the epige-
netic machinery is an attractive strategy. It has been shown
that drugs (e.g. 5-azacytidine) that suppress normal promoter
methylation inhibit EMT. The histone deacetylase inhibitor
Panobinostat (LBH589) is being considered for the treatment
of triple negative breast cancer and preliminary studies show
that the drug prevents EMT in cell lines through its influence
on ZEB transcription factors and E-Cadherin. Furthermore,
this novel drug inhibits formation of metastasis by the breast
cancer cell line MDA-MB-231 [85, 86]. The general effect of
histone deacetylation antagonizes EMT by relieving suppres-
sion of important promoters including CDH1 (E-cadherin).
The drug Eribulin mesilate that influences microtubule as-
sembly has been shown to improve survival in late-stage
breast cancer patients through an unknown mechanism. A
recent study suggests that the influence of the drug is mainly
through suppression of mesenchymal conversion, further
stressing the importance of cytoskeleton reorganization for
the completion of EMT [87].
The anti-diabetic drug metformin, that is known to possess
anti-cancer properties is reported to influence EMT. According
to a recent study, this effect is probably due to activation of the
AMPK pathway that is central to the regulation of energy me-
tabolism and can be triggered by TGFβ signals [88]. A selec-
tive inhibitor of AMPK-alpha termed Compound C, abolishes
the ability of TGFβ1 to induce apoptosis and EMT [89].
Recently, Hollier et al. demonstrated that FOXC2 transcription
factor was efficient in inducing CSC and EMT phenotype in
breast cancer cell lines. Interestingly, FOXC2 is expressed at
high level in the claudin low breast cancer subtype associated
with CSC and EMT phenotype [90]. Furthermore, they show
that PDGFR-β is upregulated in FOXC2 induced EMT and
that the FDA approved inhibitor of PDFGR, sunitinib reduced
growth of CSC and metastasis.
Closing Remarks
The branching epithelium of the adult female mammary gland
undergoes repeated rounds of proliferation, differentiation and
apoptosis during each menstruation cycle that is further exag-
gerated during pregnancy, lactation and involution. This con-
tinuous cellular remodeling has highlighted the importance of
stem and progenitor cells within the mammary epithelium that
provide the glandular epithelium with new functional cells.
Furthermore, there is increasing interest in these stem cells,
as they are believed to be targets for carcinogenic agents due
to their longevity in tissues. It is debatable, however, whether
or not it is the stem cells themselves, their progenitors or the
more differentiated cells that have acquired stem cell proper-
ties and represent the true tumor initiating cells. It is of great
importance that we are able learn more about the cellular hi-
erarchy in the mammary gland and how the cross talk between
the epithelium and stroma is maintained and how this goes
awry during breast cancer progression. The inherent plasticity
of the epithelium reflected in its ability to respond to external
cues and change phenotype towards mesenchymal morphol-
ogy via EMT is important, particularly since accumulating
evidences implicates EMT in drug resistance and tumor
relapse.
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